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Eventually, prompt targeted antibiotic
therapy resulted in reconstitution of
the outer retinal anatomic landmarks
on SD-OCT.
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Dear Editor,
N o general consensus existsregarding the best topical treat-
ment practice after cataract surgery
(CS) (Aptel et al. 2017; Juthani et al.
2017). Since no established guidelines
are available, practice patterns
throughout the world differ. Treatment
protocol with topical nonsteroidal anti-
inflammatory drugs (NSAIDs) after
CS began decades ago (Miyake 1977).
Today, NSAIDs such as ketorolac,
nepafenac, diclofenac and bromfenac
can be used to treat the postoperative
(A)
(C)
(D)
(E)
(F)
(B)
Fig. 1. (A) Fundus photography of the macular placoid lesion in the right and left eye.
(B) Truncal maculopapular cutaneous erythema at presentation. (C) SD-OCT image of the macula
in the right eye on presentation. Disruption of the outer segment structures with grainy, linear
hyperdensities and lack of external limiting membrane at presentation. (D) The ‘pitchfork sign’
(green rectangle, insert) in the right eye. (E) Serous retinal detachment and membrane-like, hyper-
reflective subretinal lesion (green rectangle, insert) in the left eye. (F) Seven months after
presentation, the outer retinal segment appeared normal in the fovea in the right eye.
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anterior chamber inflammation after
CS combined to corticosteroids or as
monotherapy.
Our institutional topical treatment
regimenwas revised in 2014 after topical
NSAIDs had shown to offer efficacy
comparable to steroids in reducing post-
operative inflammation, but with a
lower risk for adverse events (Kessel
et al. 2014). Using a standardized, com-
puterized platform for patients under-
going CS, we found that during 2015–
2018, 60% of the eyes undergoing CS
were treatedwith combinationof topical
levofloxacin and nepafenac, while
20.3% of eyes were treated with topical
levofloxacin and prednisolone acetate
(PA;Table 1). Triple combination treat-
ment with topical levofloxacin, nepafe-
nac and PA was used in <10% of our
study eyes. Noteworthy, topical PA
played an important role, especially in
eyes with the most advanced cataract, in
the eyes with lowest preoperative visual
acuity, and in the eyes with intraopera-
tive complication. Based on our study,
we could see seasonal/yearly fluctuation
in the use of the most commonly used
topical drugs and their combinations in
our institution. There was a trend of
increased use of topical PA during the
study period reflecting partially the
instinctive experience of the surgeons
to diagnosemore inflammatory reaction
and cells in the anterior chamber of our
patients using nepafenac instead of PA
(Grzybowski & Kim 2016). Part of the
yearly quartile variation was explained
by the fact that nepafenac was tem-
porarily out of stock during the last
quartile of the year 2018.
We do acknowledge the following
limitations. Our study is retrospective
with some inaccuracies in data coding
such as missing data. Of note, we could
neither assess the postoperative func-
tional visual or refraction outcomes in
our study eyes nor patient-reported
outcome measures. Neither patient-
reported tolerability issues of pre-
scribed medication could be studied
(Hovanesian & Holland 2019). In the
future, National Cataract Registry and
Co-ordination will be highly required
in Finland including preoperative risk
calculation at least to combination
ocular surgeries (Goltz et al. 2018).
Herein, incidence of endophthalmitis
was 0.0045%. In 95% of the eyes, we
used intracameral cefuroxime shown to
be 100% effective in preventing endoph-
thalmitis (Jabbarvand et al. 2016). In
Table 1. Summary of surgical characteristics and actual topical treatment in a large adult cataract
surgery cohort operated during 2015–2018.
Basic data of operated eyes
Operated eyes/patients (n) 21 962/15 994
Female/male 63/37%
ICD-code
H25.1 normal cataract 20 007 (91.1%)
H26.02 presenile cataract 0.3%
H26.1 traumatic cataract 0.07%
H26.2 related to other eye disease 7.2%
Related to other ICD category 1.3%
Preop risk stratification i.e. estimated severity of cataract
Green category/yellow/red 37.7/56.3/6.0 (%)
Mode of anaesthesia
Topical 20 864 (95%)
Peribulbar/general 1098 (5%)
Single/bilateral eye surgery 20 886 (95.1%)/
1076 (4.9%)
Anterior chamber Xylocain + PHNL 1855 (8.4%)
Viscoelastic agent
Discovisc/Viscoat/other 85.8/11.9/2.3 (%)
Trypan blue staining 1059 (4.8%)
Characteristics of anterior segment
Small pupil 3601 (16.4%)
Exfoliation syndrome+ 2174 (9.9%)
Need of pupil expansion device 1405 (6.4%)
Malyugin ring/hook 5.9%/0.5%
Phaco technique
Stop-chop 9595 (43.7%)
Divide-conquer 8731 (35.8%)
Chop 3278 (14.9%)
Other 355 (1.6%)
Location of inserted IOL
Posterior chamber 21 304 (97%)
Sulcus fixated 69 (0.3%)
Anterior chamber 24 (0.1%)
Missing info 565 (2.6%)
Intracameral antibiotic 0.1 ml
Cefuroxime 10 mg/ml 20 832 (94.8%)
Vancomycin 10 mg/ml 352 (1.6%)
Moxifloxacin 54 (0.2%)
Not known 724 (3.3%)
Nylon suture (10-0) to the main wound 219 (1%)
Target refraction
Emmetropic 18 008 (82%)
2 to 2.5 D 2525 (11.5%)
Other/missing 4.0%/2.5%
Duration of surgery
<10 min 1207 (5.5%)
11–15 min 6281 (28.6%)
16–20 min 6083 (27.7%)
>20 min 8367 (38.1%)
Topical medication
Levofloxacin 5 mg/ml + nepafenac 3 mg/ml 13 349 (60.8%)
Levofloxacin 5 mg/ml + PA 10 mg/ml 4468 (20.3%)
Levofloxacin 5 mg/ml + nepafenac 3 mg/ml + PA 10 mg/ml 1715 (7.8%)
Other, including glaucoma medication 2430 (11.1%)
Use of topical nepafenac and PA in various subgroups
Preop visual acuity (VA)
VA given in 14
792 eyes (67.4%) Use of PA and/or N
<0.1 on AR 1814 (12.3%) 33.1% used PA + 74.2% used N
0.1–0.5 on AR 11 822 (79.9%) 26.0% used PA + 73.5% used N
>0.5 on AR 1156 (7.8%) 22.7% used PA + 77.3% used N
Risk stratification i.e. Severity of cataract
Green category (normal) 21.4% of eyes used PA
Yellow (moderate) 28.7% of eyes used PA
Red (advanced) 37% of eyes used PA
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previous studies, ourmainline strategy to
use intracameral cefuroxime together
with topical levofloxacin has been shown
to lower the chance of endophthalmitis
with high-to-moderate quality evidence
(Kessel et al. 2015; Gower et al. 2017).
We use intracameral antibiotics despite
their potential risks and their role being
controversial in prophylaxis of endoph-
thalmitis post-CS (Cakır et al. 2015;
Witkin et al. 2015; Schwartz et al.
2016). Regimen of topical antibiotic use
deserves to be revised next, since resis-
tance issues are an ever-increasing prob-
lem globally.
Even though our hospital registry
data allow a tool for understanding
current clinical practice patterns in our
high-volume CS unit, more thorough
prospective clinical studies are still
needed to answer various specific ques-
tions related to ophthalmic outcome
parameters (such as final visual func-
tion, vision-related quality of life, occur-
rence of postoperative cystic macular
oedema, intraocular lens (IOL) disloca-
tion/tilt, results of combinatorial/post-
vitrectomy cataracts surgeries), and
issues related to each specific topical
therapy. In the future, the structural
data should be linked with systemic
medication and type of IOL used. We
hope that the actual use of very struc-
tured data could, however, stimulate
and set standards for other ophthalmic
departments.
References
Aptel F, Colin C, Kaderli S, Deloche C, Bron
AM, Stewart MW, Chiquet C; OSIRIS
group (2017): Management of postoperative
inflammation after cataract and complex
ocular surgeries: a systematic review and
Delphi survey. Br J Ophthalmol 101: 1–10.
Cakır B, Celik E, Aksoy N€O, Bursalı €O, Ucak
T, Bozkurt E & Alagoz G (2015): Toxic
anterior segment syndrome after uncompli-
cated cataract surgery possibly associated
with intracamaral use of cefuroxime. Clin
Ophthalmol 17: 493–497.
Goltz DE, Baumgartner BT, Politzer CS,
DiLallo M, Bolognesi MP & Seyler TM
(2018): The American college of surgeons
national surgical quality improvement pro-
gram surgical risk calculator has a role in
predicting discharge to post-acute care in
total joint arthroplasty. J Arthroplasty 33:
25–29.
Gower EW, Lindsley K, Tulenko SE, Nanji
AA, Leyngold I & McDonnell PJ (2017):
Perioperative antibiotics for prevention of
acute endophthalmitis after cataract sur-
gery. Cochrane Database Syst Rev 2:
CD006364.
Grzybowski A & Kim SJ (2016): Corticos-
teroids substituted by nonsteroidal antiin-
flammatory drugs: Is it justified by evidence-
based medicine? J Cataract Refract Surg 42:
510–511.
Hovanesian J & Holland E (2019): Tolerability
and toxicity of topically applied nepafenac
0.3% compared with generic ketorolac 0.5. J
Cataract Refract Surg 45: 174–180.
Jabbarvand M, Hashemian H, Khodaparast
M, Jouhari M, Tabatabaei A & Rezaei S
(2016): Endophthalmitis occurring after
cataract surgery: outcomes of more than
480 000 cataract surgeries, epidemiologic
features, and risk factors. Ophthalmology
123: 295–301.
Juthani VV, Clearfield E & Chuck RS (2017):
Non-steroidal anti-inflammatory drugs
versus corticosteroids for controlling inflam-
mation after uncomplicated cataract sur-
gery. Cochrane Database Syst Rev 7:
CD010516.
Kessel L, Tendal B, Jørgensen KJ, Erngaard
D, Flesner P, Andresen JL & Hjortdal J
(2014): ost-cataract prevention of inflamma-
tion and macular edema by steroid and
nonsteroidal anti-inflammatory eye drops: a
systematic review. Ophthalmology 121:
1915–1924.
Kessel L, Flesner P, Andresen J, Erngaard D,
Tendal B & Hjortdal J (2015): Antibiotic
prevention of postcataract endophthalmitis:
a systematic review and meta-analysis. Acta
Ophthalmol 93: 303–317.
Miyake K (1977): Prevention of cystoid
macular edema after lens extraction by
topical indomethacin (I). A preliminary
report. Albrecht Von Graefes Arch Klin
Exp Ophthalmol 203: 81–88.
Schwartz SG, Flynn HW Jr, Grzybowski A,
Relhan N & Ferris FL (2016): Intracam-
eral antibiotics and cataract surgery:
endophthalmitis rates, costs, and steward-
ship. Ophthalmology 123: 1411–1413.
Witkin AJ, Shah AR, Engstrom RE et al.
(2015): Postoperative hemorrhagic occlusive
retinal vasculitis: expanding the clinical
spectrum and possible association with van-
comycin. Ophthalmology 122: 1438–1451.
Correspondence:
Sirpa Loukovaara, MD, PhD
Unit of Vitreoretinal Surgery
Department of Ophthalmology
University of Helsinki and Helsinki University
Hospital
Haartmaninkatu 4 C, 00290 Helsinki
Finland
Tel: +358 50 4271566
Fax: +358 9 47175100
Email: sirpa.loukovaara@hus.fi
This work was supported by TYH2018127 and
TYH2019232 grants (SL).
Table 1. (Continued)
Intraoperative complications
in the whole cohort
400 (1.8%)
Anterior capsule tear 87 (21.8%) 42.5% used PA + 55.2% used N
Iris damage 118 (29.5%) 47.5% used PA + 59.3% used N
Posterior capsule rupture 110 (27.5%) 48.25 used PA + 59.1% used N
Dropped nucleus 16 (4%) 56.3% used PA + 75% used N
Other 69 (17.2%)
Changes in PA use during 2015–2018 Operated eyes (n) Used medication
3rd quartile of the year 2015 903 9% used PA + 75.2% used N
3rd quartile of the year 2016 852 14.3% used PA + 92.7% used N
3rd quartile of the year 2017 994 22.4% used PA + 89.0% used N
3rd quartile of the year 2018 1395 36.3% used PA + 83.1% used N
Postoperative endophthalmitis during 2015–2018
Propionibacterium acnes 1 eye (0.0045%)
The eyes with cataract were coded with International Classification of Disease (ICD)-codes.
Surgical risk stratification of operated eyes was as follows: normal cataract (green; nuclear
sclerosis ++), moderate cataract (yellow; nuclear sclerosis +++) and advanced cataract (red; no red
reflex, loose zonules, exfoliation ++, VA < 0.1). The surgical technique was the standard
minimally invasive phacoemulsification technique (Infinity/Centurion Vision System, Alcon
Laboratories, Inc., Fort Worth, TX, USA) with a 2.4–2.75 mm clear corneal incision. In the
uncomplicated cataract surgeries, single-piece acrylic monofocal IOL (AMO Tecnis, Johnson &
Johnson Surgical Vision Inc., Santa Ana, CA, USA) or three-piece aspheric acrylic IOL (Tecnis
ZA9003, Abbott Medical Optics Inc, Santa Ana, CA, USA) was folded and inserted using a lens
injector to the capsular bag (posterior chamber IOL). Data were collected from the operating
room management system consisting of all cataract operations in the BCB Medical cataract
database (BCB cataract database, Turku, Finland) between 1 January 2015 and 31 December
2018. The study represents secondary use of registered surgical data and is without patient contact.
AR = autorefractometer, IOL = intraocular lens, N = nepafenac, PA = prednisolone acetate,
PHNL = phenylephrine 10%, VA = visual acuity.
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